摘要
异羟肟酸是一类很有前途的化合物,具有经证实的抗肿瘤潜力,主要是因为它们能够抑制组蛋白脱乙酰酶的活性。对现代实验数据的分析表明,异羟肟酸具有广泛的生物活性,这使它们成为对抗神经病理学的同样有价值的候选者。异羟肟酸的一个特征是它们能够同时作用于几个有希望的分子靶点,以纠正神经病理学和肿瘤疾病,从而表现出多功能性。本综述讨论了异羟肟酸对癌症关键部位和神经退行性疾病发病机制的影响。与氧化应激、线粒体功能和组蛋白脱乙酰酶类金属酶活性相关的过程中的病理变化,作为病理状态表观遗传调控的主要环节,就是这样的分子靶点。
关键词: 异羟肟酸、癌症、神经退行性疾病、氧化应激、线粒体、组蛋白脱乙酰酶。
Current Medicinal Chemistry
Title:The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Volume: 28 Issue: 39
关键词: 异羟肟酸、癌症、神经退行性疾病、氧化应激、线粒体、组蛋白脱乙酰酶。
摘要: Hydroxamic acids are a promising class of chemical compounds with proven antitumor potential, primarily due to their ability to inhibit the activity of histone deacetylase enzymes. The analysis of modern experimental data shows a wide range of biological activities of hydroxamic acids, which make them equally worthy candidates for the fight against neuropathologies. A characteristic feature of hydroxamic acids is their ability to act simultaneously on several promising molecular targets for the correction of both neuropathologies and oncological diseases, thereby exhibiting multifunctionality. This review discusses the effect of hydroxamic acids on key parts of cancer and neurodegenerative disorders' pathogenesis. Pathological changes in the processes associated with oxidative stress, the functioning of mitochondria, and the activity of metal enzymes of the class of histone deacetylases, as the main links in the epigenetic regulation of pathological conditions, are such molecular targets.
Export Options
About this article
Cite this article as:
The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents, Current Medicinal Chemistry 2021; 28 (39) . https://dx.doi.org/10.2174/0929867328666201218123154
DOI https://dx.doi.org/10.2174/0929867328666201218123154 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dendrogenin A: A Mammalian Metabolite of Cholesterol with Tumor Suppressor and Neurostimulating Properties
Current Medicinal Chemistry Biochemical Markers of Bone Turnover and their Role in Osteoporosis Diagnosis: A Narrative Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Crosstalk Between the Matrix Metalloprotease System and the Chemokine Network in Acute Myeloid Leukemia
Current Medicinal Chemistry From Target Therapy to miRNA Therapeutics of Human Multiple Myeloma: Theoretical and Technological Issues in the Evolving Scenario
Current Drug Targets Antisense Strategies
Current Molecular Medicine Antibody Fusion Proteins: Applications in Brain Targeting
Current Medicinal Chemistry - Central Nervous System Agents The Use of Thalidomide in Myeloma Therapy as an Effective Anticancer Drug
Current Cancer Drug Targets Development of a Non Invasive NGF-Based Therapy for Alzheimers Disease
Current Alzheimer Research Strategies for Targeting the Multidrug Resistance-1 (MDR1)/P-gp Transporter in Human Malignancies
Current Cancer Drug Targets Angiogenesis Inhibitors: Perspectives for Medical, Surgical and Radiation Oncology
Current Pharmaceutical Design Antitumoral Potential of Snake Venom Phospholipases A2 and Synthetic Peptides
Current Pharmaceutical Biotechnology Update on the Use of Biologics in Lupus
Current Pharmaceutical Biotechnology A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials
Current Pharmaceutical Design Cutting the Limits of Aminobisphosphonates: New Strategies for the Potentiation of their Anti-Tumour Effects
Current Cancer Drug Targets Drug-Mediated Targeted Disruption of Multiple Protein Activities Through Functional Inhibition of the Hsp90 Chaperone Complex
Current Medicinal Chemistry Recent Advances in the Design and Synthesis of c-Met Inhibitors as Anticancer Agents (2014-Present)
Current Medicinal Chemistry The Role of Fibroblast Growth Factors in Tumor Growth
Current Cancer Drug Targets CCR1 Antagonists: What Have We Learned From Clinical Trials
Current Topics in Medicinal Chemistry Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab
Endocrine, Metabolic & Immune Disorders - Drug Targets Peptide Vaccines for Cancer Therapy
Recent Patents on Inflammation & Allergy Drug Discovery